Clinically amyopathic dermatomyositis during the COVID-19 pandemic | Zendy

Masakazu Kitamura | Zendy; Hiroshi Sugimoto | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Clinically amyopathic dermatomyositis during the COVID-19 pandemic

Author(s) -

Masakazu Kitamura,

Hiroshi Sugimoto

Publication year - 2021

Publication title -

oxford medical case reports

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.169

H-Index - 9

ISSN - 2053-8855

DOI - 10.1093/omcr/omab061

Subject(s) - medicine , dermatomyositis , covid-19 , prednisolone , pandemic , dermatology , computed tomography , radiology , pathology , disease , infectious disease (medical specialty)

An 84-year-old Japanese woman presented to our hospital with a month-long dry cough during the coronavirus disease 2019 (COVID-19) pandemic. She also had skin lesions on her fingers from 3 months prior. A chest computed tomography (CT) scan showed bilateral ground- glass opacities with a subpleural distribution, similar to the findings of COVID-19. The results of COVID-19 tests were negative. The titer of the anti-melanoma differentiation-associated gene 5 (MDA5) antibody was elevated. Consequently, we confirmed the diagnosis of clinically amyopathic dermatomyositis (CADM) and then administered oral prednisolone combined with tacrolimus. After the treatment, her symptoms, skin lesions and CT findings were gradually resolved.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research